The purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (ADT) for participants with locally-advanced and metastatic hormone-sensitive prostate cancer (mHSPC). This study will also quantify the importance of administration factors related to convenience relative to treatment outcomes.
The study will develop and administer a discrete-choice experiment (DCE) to quantify tradeoff preferences of participants with mHSPC and locally-advanced prostate cancer in various countries. Data/surveys are being collected in: United States, Canada, UK, France, Spain, Japan, China and South Korea.
Study Type
OBSERVATIONAL
Enrollment
1,020
Duke Clinical Research Institute
Durham, North Carolina, United States
Log-odds (preference weights) by participant cancer type and country
Log-odds indicate participants' relative preferences for treatments with each attribute level in the study, all else equal.
Time frame: 1 day (once through survey)
Relative importance weights by participant type and country
These weights indicate the overall influence of each study attribute on choice.
Time frame: 1 day (once through survey)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.